Potential Drug Targets and Biomarkers for LAMB2-Involved Diseases

Target Name: LAMB2

NCBI ID: G3913

Potential Drug Targets and Biomarkers for LAMB2-Involved Diseases

LAMB2 (Laminin-14 subunit beta) is a protein that is expressed in a variety of tissues throughout the body, including the skin, hair, nails, and bones. It is a component of the cytoskeleton and is involved in the structure and function of cells. LAMB2 has also been shown to play a role in the development and progression of various diseases, including cancer. As a result, LAMB2 has generated a lot of interest as a potential drug target or biomarker.

The LAMB2 protein is composed of 14 subunits that are held together by disulfide bonds. The subunits include a alpha-helical domain, a beta-sheet, and a gamma-prime tail. The alpha-helical domain is the region of the protein that is responsible for its cytoskeleton-related functions, such as providing structural stability and participating in the cytoskeleton-associated signaling pathways. The beta-sheet region is the region of the protein that is involved in the formation of helices and is thought to play a role in the regulation of the cytoskeleton. The gamma-prime tail is the region of the protein that is responsible for its ability to interact with other proteins and for its role in signaling pathways.

LAMB2 has been shown to be involved in a number of different signaling pathways, including the regulation of cell growth, the cytoskeleton-associated signaling pathway, and the regulation of cell adhesion. For example, studies have shown that LAMB2 can interact with the protein F-actin and that this interaction is involved in the regulation of cell adhesion. Additionally, LAMB2 has been shown to play a role in the regulation of cell cycle progression, as well as in the regulation of apoptosis.

As a result of its involvement in these signaling pathways, LAMB2 has been shown to be a potential drug target or biomarker for a variety of diseases. For example, studies have shown that LAMB2 is involved in the development and progression of various cancers, including breast, ovarian, and prostate cancers. Additionally, LAMB2 has been shown to be involved in the regulation of cell adhesion, which could make it a potential target for diseases that are characterized by disruptions in cell adhesion, such as cancer.

In addition to its potential as a drug target or biomarker, LAMB2 has also generated interest as a potential therapeutic agent. For example, studies have shown that LAMB2 can be expressed in cancer cells and that this expression is associated with the development and progression of cancer. Additionally, studies have shown that LAMB2 can interact with the protein PDGF-BB and that this interaction is involved in the regulation of cell growth and the development of cancer. As a result, LAMB2 has been shown to be a potential target for cancer therapies that target the regulation of cell growth and the cytoskeleton.

Overall, LAMB2 is a protein that is involved in a number of different signaling pathways and has been shown to play a role in the development and progression of various diseases. As a result, LAMB2 has generated a lot of interest as a potential drug target or biomarker and as a therapeutic agent. Further research is needed to fully understand the role of LAMB2 in these processes and to develop effective treatments for diseases in which it is involved.

Protein Name: Laminin Subunit Beta 2

Functions: Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components

More Common Targets